News
Admittedly, in the relative near term, it’s difficult to frame U stock as cheap. In the past 52 weeks, for example, the ...
Again.Marvel and DC will go head-to-head once more in the summer box office, just as both of the comic book movie companies ...
After Decades Without Progress in Glioblastoma, Diakonos Stirs Up Interest in Dendritic Cell Vaccine
The firm is launching a Phase II trial of its dendritic cell vaccine following promising preliminary efficacy and favorable safety results in Phase I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback